Mortality and Its Predictors among Adult Human Immune-Deficiency Virus-Infected Patients Attending Their Antiretroviral Treatment at Health Centers, Addis Ababa, Ethiopia: Multicenter Retrospective Cohort Study
Table 3
Bivariable and multivariable Cox-proportional regression analysis on predictors of mortality in adult patients under ART in health centers at Addis Ababa, Ethiopia, 2014–2019.
Variable
Survival status
CHR (95% CI)
AHR (95% CI)
Censored
Died
Age
17–34
210
9
1
35–50
298
22
1.67 (0.76, 3.62)
2.07 (0.90, 4.79)
>50
49
25
10.48 (4.88, 22.55)
4.89 (2.00, 11.98)
Occupation
Formal employee (Gov’t/NGO)
168
9
1
daily Laborer
292
28
1.69 (0.80, 3.59)
1.72 (0.74, 3.98)
Farmer/housewife
93
18
3.47 (1.56, 7.74)
1.41 (0.55, 3.64)
Marital status
Single
293
17
1
Married
145
13
1.63 (0.7953.37)
1.75 (0.73, 4.17)
Widowed
44
11
3.96 (1.85, 8.477)
0.92 (0.31, 2.72)
Divorced
76
14
3.06 (1.51, 6.21)
1.79 (0.75, 4.24)
Active TB status
No
455
15
1
1
Yes
103
40
8.54 (4.78, 15.25)
3.46 (1.52, 7.91)
WHO clinical staging
stage I
271
6
1
1
stage II
140
5
1.27 (0.40, 4.01)
0.43 (0.11, 1.59)
stage III
79
15
6.73 (2.74, 16.52)
1.78 (0.57, 5.56)
Stage IV
68
29
14.64 (6.40, 33.49)
4.55 (1.72, 12.02)
Functional status
Working
381
20
1
1
Ambulatory
155
13
1.40 (0.70, 2.81)
0.96 (0.423, 2.197
Bedridden
22
22
11.56 (6.33, 21.11)
2.89 (1.26, 6.60)
Drug allergy
No
355
21
1
1
Yes
203
34
2.50 (0.46, 4.28)
0.95 (0.46, 1.95)
Drug adherence
Yes
425
31
1
1
No
133
24
2.16 (1.27, 3.67)
1.76 (1.23, 3.33)
Co-trimoxazole therapy
No
308
42
2.30 (1.25, 4.22)
2.56 (1.25, 5.24)
Yes
248
14
1
1
BMI
<18.5
151
32
3.11 (1.83, 5.28)
2.59 (1.37, 4.90)
≥18.5
405
23
1
CD4+ counts
<200/ul
39
28
9.012 (5.33, 15.22)
2.77 (1.30, 5.92)
≥200/ul
518
28
1
Baseline hemoglobin
<10
15
18
12.09 (6.86, 21.31)
0.612 (0.28, 1.33)
≥10
540
37
1
1
Note. ,, COR: crude odds ratio; AOR = adjusted odds ratio; and CI = confidence interval.
